| Literature DB >> 35280269 |
Alicia Northall1, Budhaditya Mukhopadhyay1, Miriam Weber2, Susanne Petri3, Johannes Prudlo4,5, Stefan Vielhaber2, Stefanie Schreiber2,6,7, Esther Kuehn1,6,7.
Abstract
Introduction: Bulbar symptoms, including difficulty swallowing and speaking, are common in amyotrophic lateral sclerosis (ALS) and other neurological disorders, such as stroke. The presence of bulbar symptoms provides important information regarding clinical outcomes, such as survival time after diagnosis. Nevertheless, there are currently no easily accessible, quantitative methods to measure bulbar function in patients.Entities:
Keywords: amyotrophic lateral sclerosis; bulbar; neural network; quantification; tongue
Year: 2022 PMID: 35280269 PMCID: PMC8914067 DOI: 10.3389/fneur.2022.838191
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Demographic variables for patients with amyotrophic lateral sclerosis (ALS) and healthy controls.
|
|
|
| |||
|---|---|---|---|---|---|
|
|
|
|
|
| |
| Age (years) | 53 (16) | 53 (23) | 24 | 0.10 | 0.920 |
| Education (years) | 15 (3) | 15 (3) | 24 | −0.80 | 0.431 |
| Gender (M: F) | 6:4 | 5:11 | 24 | −0.145 | 0.161 |
Group differences were measured by using the independent-samples t-tests.
Demographic information for patients with ALS.
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Lower limb | Left | UMND | 74 | F | 15 | 176 | 92 | Definite | 13 |
| 2 | Lower limb | Left | Classical ALS | 36 | M | 16 | 168 | 64 | Probable | 26 |
| 3 | Upper limb | Right | Classical ALS | 48 | M | 13 | 185 | 100 | Definite | 186 |
| 4 | Upper limb | Left | Classical ALS | 61 | M | 15 | 180 | 85 | Probable | 11 |
| 5 | Upper limb | Left | Classical ALS | 66 | M | 18 | 180 | 74 | Probable | 11 |
| 6 | Upper limb | Left | UMND | 60 | M | 12 | 166 | 90 | Definite | 11 |
| 7 | Upper limb | Left | LMND | 52 | F | 12 | 158 | 60 | Possible | 18 |
| 8 | Upper limb | Right | Classical ALS | 20 | F | 12 | 160 | 90 | Definite | 2 |
| 9 | Bulbar | Bulbar | LMND | 64 | F | 13 | 162 | 59 | Possible | 6 |
| 10 | Bulbar | Bulbar | UMND | 53 | M | 21 | 179 | 77 | Probable | 33 |
| Group mean (SD) | 53 (16) | 15 (3) | 171 (10) | 79 (15) | 32 (55) |
UMND, Upper Motor Neuron Dominant; LMND, Lower Motor Neuron Dominant; El-Escorial, revised El-Escorial criteria.
Clinical scores of patients with ALS.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| 1 | 25 | 7 | 1.8 | 53 | 26 |
| 2 | 45 | 12 | 0.1 | 22 | 15 |
| 3 | 37 | 12 | 0.1 | 21 | 2 |
| 4 | 41 | 11 | 0.6 | 29 | 6 |
| 5 | 41 | 9 | 0.6 | 31 | 2 |
| 6 | 40 | 10 | 0.7 | 32 | 11 |
| 7 | 42 | 12 | 0.3 | 22 | 16 |
| 8 | 14 | 8 | 17 | 28 | - |
| 9 | 47 | 11 | 0.2 | 28 | 1 |
| 10 | 33 | 7 | 0.5 | 62 | 2 |
| Group mean (SD) | 37 (10) | 10 (2) | 2.2 (5.2) | 33 (14) | 9 (9) |
Disease progression rate = (48-ALSFRS-R)/disease duration (months); ALSFRS-R, ALS functional rating scale-revised; UMN-Penn, Penn Upper Motor Neuron score; CNS-BFS, Center for Neurologic Study-Bulbar Function Scale; (– indicates missing data).
Figure 1Overview of Tongue Tracker (TT). The videos were first pre-processed via steps detailed in the text (see pre-processing section). (A) The face and mouth were detected and extracted from each frame of the pre-processed videos. (B) The tongue was then detected by using a trained neural network, resulting in a binary image showing the location of the tongue in each video frame. (C) A record of the location of the tongue, either in the left or right portion of the frame, was recorded and saved for extracting kinematic features of the tongue. The code can be accessed here: https://github.com/BudhaTronix/Automated-Video-Analysis-Tool-for-Quantifying-Bulbar-Function.git.
Figure 2Validation results. Relationship between manual and automated (TT) methods for quantifying bulbar function based on the same video clips. The total number of sweeps are plotted separately for patients (N = 10) and healthy controls (N = 16). Correlations marked ** are significant at the 5% level.
Overview over tongue kinematic features.
|
| |||||
|---|---|---|---|---|---|
|
|
|
|
| ||
| Patient 1 vs. healthy controls ( | Number of sweeps | 16 vs. 27 (11.71) | 15 | 3.76 | 0.002 |
| Average sweep duration | 0.30 vs. 0.23 (.13) | 15 | −2.18 | 0.046 | |
| Number of errors | 1 vs. 2.44 (3.25) | 15 | 1.77 | 0.097t | |
| Patient 4 vs. healthy controls ( | Number of sweeps | 32 vs. 27 (11.71) | 15 | −1.71 | 0.108 |
| Average sweep duration | 0.17 vs. 0.23 (.13) | 15 | 1.73 | 0.105 | |
| Number of errors | 4 vs. 2.44 (3.25) | 15 | −1.93 | 0.073t | |
| Patient 5 vs. healthy controls ( | Number of sweeps | 17 vs. 27 (11.71) | 15 | 3.42 | 0.004 |
| Average sweep duration | 0.30 vs. 0.23 (.13) | 15 | −2.18 | 0.046 | |
| Number of errors | 3 vs. 2.44 (3.25) | 15 | −0.69 | 0.499 | |
| Patient 6 vs. healthy controls ( | Number of sweeps | 18 vs. 27 (11.71) | 15 | 3.02 | 0.008 |
| Average sweep duration | 0.28 vs. 0.23 (.13) | 15 | −1.58 | 0.136 | |
| Number of errors | 6 vs. 2.44 (3.25) | 15 | −4.39 |
| |
| Patient 8 vs. healthy controls ( | Number of sweeps | 15 vs. 27 (11.71) | 15 | 4.10 |
|
| Average sweep duration | 0.33 vs. 0.23 (.13) | 15 | −3.08 | 0.008 | |
| Number of errors | 4 vs. 2.44 (3.25) | 15 | −1.93 | 0.073t | |
| Patient 9 vs. healthy controls ( | Number of sweeps | 12 vs. 27 (11.71) | 15 | 5.12 |
|
| Average sweep duration | 0.45 vs. 0.23 (.13) | 15 | −6.68 |
| |
| Number of errors | 4 vs. 2.44 (3.25) | 15 | −1.93 | 0.073t | |
| Patient 10 vs. healthy controls ( | Number of sweeps | 22 vs. 27 (11.71) | 15 | 1.71 | 0.110 |
| Average sweep duration | 0.22 vs. 0.23 (.13) | 15 | 0.22 | 0.825 | |
| Number of errors | 3 vs. 2.44 (3.25) | 15 | −0.69 | 0.499 | |
| Patient 9 vs. limb-onset patients ( | Number of sweeps | 12 vs. 19.13 (7.22) | 7 | 2.79 | 0.027 |
| Average sweep duration | 0.45 vs. 0.30 (.13) | 7 | −4.19 | 0.004 | |
| Number of errors | 4 vs. 2.75 (2.19) | 7 | −1.62 | 0.150 | |
| Patient 10 vs. limb-onset patients ( | Number of sweeps | 22 vs. 19.13 (7.22) | 7 | −1.13 | 0.297 |
| Average sweep duration | 0.22 vs. 0.30 (.13) | 7 | 2.03 | 0.082 | |
| Number of errors | 3 vs. 2.75 (2.19) | 7 | −0.32 | 0.756 | |
| All patients ( | Number of sweeps | 18.70 (6.85) vs. 27 (11.71) | 24 | 2.03 | 0.050t |
| Average sweep duration | 0.30 (.11) vs. 0.23 (.13) | 24 | −1.51 | 0.150 | |
| Number of errors | 2.90 (1.97) vs. 2.44 (3.25) | 24 | −0.41 | 0.690 | |
Four types of comparisons were made: (i) individual bulbar-impaired limb-onset patients with ALS (patients 1, 4, 5, 6, and 8) and healthy controls (lines 1–5), (ii) individual bulbar-onset patients with ALS (patients 9 and 10) and healthy controls (lines 6 and 7), (iii) individual bulbar-onset patients with ALS (patients 9 and 10) and limb-onset patients with ALS (lines 8 and 9), and (iv) all the patients with ALS (regardless of onset type) and healthy controls (line 10). Statistics are reported as one-sample t-tests and two-sample t-tests
(
and
are significant at the 5 and 1% uncorrected level, respectively; those marked in bold remained significant at the Bonferroni-corrected threshold of p < 0.0024); differences marked .
Figure 3Group differences in tongue movement features. Shown are mean number of sweeps, mean sweep duration and mean number of errors. Top row: Box plots show patients with amyotrophic lateral sclerosis (ALS) (N = 10, circles, red) and healthy controls (N = 16, squares, blue). Middle row: Box plots show bulbar-onset patients (N = 2, triangles) and healthy controls (N = 16, squares, blue). Bottom row: Box plots show bulbar-onset patients (N = 2, triangles) and limb-onset patients (N = 16, circles, yellow), where limb-onset patients with bulbar impairment are shaded circles (Individual patients marked * are significant when compared to the healthy controls or limb-onset patients).